Accessing the therapeutic potential of immunostimulatory nucleic acids

Current Opinion in Immunology

Volumn 20, Issue 4, 2008, Pages 389-395

  Barchet, Winfried ^a   Wimmenauer, Vera ^a   Schlee, Martin ^a   Hartmann, Gunther ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' TRIPHOSPHATE; AMPLIGEN; ANTHRAX VACCINE; ANTINEOPLASTIC AGENT; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; LIGAND; MELANOMA DIFFERENTIATION ASSOCIATED PROTEIN 5; MELANOMA VACCINE; PHOSPHATE; POLYINOSINIC POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; SINGLE STRANDED RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANTHRAX; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CYTOSOL; DENDRITIC CELL; DESENSITIZATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ENDOSOME; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INNATE IMMUNITY; MELANOMA; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

ANIMALS; B-LYMPHOCYTES; DEAD-BOX RNA HELICASES; DENDRITIC CELLS; DNA; HUMANS; LIGANDS; OLIGODEOXYRIBONUCLEOTIDES; POLY I-C; RECEPTORS, RETINOIC ACID; RNA; TOLL-LIKE RECEPTORS;

EID: 48549097394     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.07.007     Document Type: Review

References (56)

1. Pichlmair A., and Reis e Sousa C. Innate recognition of viruses. Immunity 27 (2007) 370-383. This review is an encompassing and insightful resource summarizing the current knowledge in this rapidly moving field.
2. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., and Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
3. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., Furutani Y., Yano O., Kataoka T., Sudo T., et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 72 (1984) 955-962
4. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
5. ••], this study is the first to implicate TLR9 in the innate recognition of viruses.
6. ••].
7. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., Zinkernagel R., and Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10 (2004) 187-192
8. Krieg A.M., Efler S.M., Wittpoth M., Al Adhami M.J., and Davis H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 27 (2004) 460-471
9. Kanzler H., Barrat F.J., Hessel E.M., and Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13 (2007) 552-559
10. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5 (2006) 471-484. This review gives an in depth assessment of the opportunities and the challenges encountered toward using CpG ODN in the clinics.
11. Latz E., Verma A., Visintin A., Gong M., Sirois C.M., Klein D.C., Monks B.G., McKnight C.J., Lamphier M.S., Duprex W.P., et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 8 (2007) 772-779
12. Haas T., Metzger J., Schmitz F., Heit A., Muller T., Latz E., and Wagner H. The DNA sugar backbone 2′ deoxyribose determines toll-like receptor 9 activation. Immunity 28 (2008) 315-323. This study highlights the influence of the DNA backbone chemistry in sustaining or blocking activation of TLR9.
13. Lund J.M., Alexopoulou L., Sato A., Karow M., Adams N.C., Gale N.W., Iwasaki A., and Flavell R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101 (2004) 5598-5603
14. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., and Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 (2002) 196-200
15. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1531
16. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., and Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
17. Barchet W., Krug A., Cella M., Newby C., Fischer J.A., Dzionek A., Pekosz A., and Colonna M. Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. Eur J Immunol 35 (2005) 236-242
18. Diebold S.S., Massacrier C., Akira S., Paturel C., Morel Y., and Reis e Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol 36 (2006) 3256-3267
19. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., Lipford G., and Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3 (2002) 499
20. Forsbach A., Nemorin J.G., Montino C., Muller C., Samulowitz U., Vicari A.P., Jurk M., Mutwiri G.K., Krieg A.M., Lipford G.B., et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 180 (2008) 3729-3738
21. Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X., Tomai M.A., Alkan S.S., and Vasilakos J.P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174 (2005) 1259-1268
22. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
23. Bell J.K., Askins J., Hall P.R., Davies D.R., and Segal D.M. The dsRNA binding site of human Toll-like receptor 3. Proc Natl Acad Sci U S A 103 (2006) 8792-8797
24. Liu L., Botos I., Wang Y., Leonard J.N., Shiloach J., Segal D.M., and Davies D.R. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320 (2008) 379-381. The cocrystal structure of dsRNA with a TLR3 dimer shows that all amino acids contacts at the four binding locations are with the dsRNA backbone, which suggests ligand recognition irrespective of the base pair sequence.
25. Zhang S.Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P., Segal D., Sancho-Shimizu V., Lorenzo L., Puel A., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317 (2007) 1522-1527
26. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mitchell W.M., Alexopoulou L., Flavell R.A., and Sidwell R.W. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol 178 (2007) 5200-5208
27. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J., Yamasaki S., Itaya M., Pan Y., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452 (2008) 591-597. This study questions the relevance of gene-silencing by siRNAs developed for the treatment of macular degeneration, and instead establishes TLR3-mediated immuneactivation as the mechanism for the observed antiangiogenetic effect.
28. Trumpfheller C., Caskey M., Nchinda G., Longhi M.P., Mizenina O., Huang Y., Schlesinger S.J., Colonna M., and Steinman R.M. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A 105 (2008) 2574-2579
29. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., and Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5 (2004) 730-737. The initial description of the immune function of RIG-I, which revolutionized the concept of cytosolic recognition of viral RNA.
30. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., Tsujimura T., Takeda K., Fujita T., Takeuchi O., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23 (2005) 19-28
31. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314 (2006) 994-997
32. Pichlmair A., Schulz O., Tan C.P., Naslund T.I., Liljestrom P., Weber F., and Sousa C.R.E. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314 (2006) 997-1001
33. Kim D.H., Longo M., Han Y., Lundberg P., Cantin E., and Rossi J.J. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 22 (2004) 321-325
34. Cui S., Eisenacher K., Kirchhofer A., Brzozka K., Lammens A., Lammens K., Fujita T., Conzelmann K.K., Krug A., and Hopfner K.P. The C-terminal regulatory domain is the RNA 5′-triphosphate sensor of RIG-I. Mol Cell 29 (2008) 169-179
35. Takahasi K., Yoneyama M., Nishihori T., Hirai R., Kumeta H., Narita R., Gale Jr. M., Inagaki F., and Fujita T. Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol Cell 29 (2008) 428-440
36. Habjan M., Andersson I., Klingstrom J., Schumann M., Martin A., Zimmermann P., Wagner V., Pichlmair A., Schneider U., Muhlberger E., et al. Processing of genome 5′ termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. PLoS ONE 3 (2008) e2032
37. ••], established the nonredundant function of MDA-5 for the detection of Picornaviruses and the synthetic ligand poly I:C.
38. ••].
39. Field A.K., Tytell A.A., Lampson G.P., and Hilleman M.R. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci U S A 58 (1967) 1004-1010
40. Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., Hiiragi A., Dermody T.S., Fujita T., and Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205 7 (2008) 1601-6010. This study proposes that RIG-I and MDA-5 complement each other in preferentially recognizing dsRNA of different length. In this context, 5′-triphosphate ends are shown not to be required for RIG-I activation.
41. ••], this study first proposed a possible antiviral mechanism activated by the detection of cytosolic B-form DNA.
42. ••].
43. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448 (2007) 501-505
44. Ishii K.J., Kawagoe T., Koyama S., Matsui K., Kumar H., Kawai T., Uematsu S., Takeuchi O., Takeshita F., Coban C., et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451 (2008) 725-729. This study highlights cytosolic DNA detection as a vital mechanism for the function of DNA vaccines.
45. Corey D.R. Chemical modification: the key to clinical application of RNA interference?. J Clin Invest 117 (2007) 3615-3622
46. Novobrantseva T.I., Akinc A., Borodovsky A., and de Fougerolles A. Delivering silence: advancements in developing siRNA therapeutics. Curr Opin Drug Discov Dev 11 (2008) 217-224
47. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11 (2005) 263-270
48. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur J Immunol 36 (2006) 1222-1230
49. Robbins M., Judge A., Liang L., McClintock K., Yaworski E., and MacLachlan I. 2′-O-Methyl-modified RNAs act as TLR7 antagonists. Mol Ther 15 (2007) 1663-1669
50. Sioud M., Furset G., and Cekaite L. Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem Biophys Res Commun 361 (2007) 122-126
51. Eberle F., Giessler K., Deck C., Heeg K., Peter M., Richert C., and Dalpke A.H. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol 180 (2008) 3229-3237
52. Kariko K., Buckstein M., Ni H., and Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23 (2005) 165-175
53. Baccala R., Hoebe K., Kono D.H., Beutler B., and Theofilopoulos A.N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13 (2007) 543-551
54. Kanneganti T.D., Ozoren N., Body-Malapel M., Amer A., Park J.H., Franchi L., Whitfield J., Barchet W., Colonna M., Vandenabeele P., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440 (2006) 233-236
55. Muruve D.A., Petrilli V., Zaiss A.K., White L.R., Clark S.A., Ross P.J., Parks R.J., and Tschopp J. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452 (2008) 103-107
56. McCartney SA, Thackray LB, Gitlin L, Gilfillan S, Virgin Iv HW, Colonna M: MDA-5 recognition of a murine norovirus. PLoS Pathog 2008, 4:e1000108.